News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Australian Regulator Rejects Zeltia Group’s Cancer Drug Yondelis
November 12, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MADRID, Nov 12 (Reuters) - Spanish drug company Zeltia's (ZEL.MC) application to register its key Yondelis anti-cancer drug in Australia has been rejected, the country's Advisory Committee on Prescription Medicines (APCM) said in a report.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Regulatory
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
February 25, 2026
·
2 min read
·
Tristan Manalac
Podcast
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
February 25, 2026
·
2 min read
·
Heather McKenzie
FDA
Opinion: Balancing Safety Access in Rare Disease—Lessons From Sarepta
February 25, 2026
·
6 min read
·
Joshua R. Mansbach
Manufacturing
Roche Seeks Antibiotic Partner as Rising Manufacturing Costs Drive Supply Rethink
February 24, 2026
·
1 min read
·
Nick Paul Taylor
